Drugs / Thyroxine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06087068 | Aug 2022 → Jul 2026 overdue | thyroid gland papillary carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04415658 | Dec 2020 → Nov 2022 | heart failure | Washington University School of Medicine | Completed | Mixed |
| Phase 41 trial | ||||||
| Phase 4 | NCT00111735 | Apr 2003 → Mar 2005 | hypothyroidism | Sir Charles Gairdner Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03712683 | Sep 2016 → Jul 2017 | hypothyroidism, pregnancy disorder with abortive outcome | Hawler Medical University | Completed | No outcome recorded |
| — | NCT02086799 | Jul 2014 → Jul 2016 | asthma | Rambam Health Care Campus | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1/2 | NCT00238030 Comparator | Dec 2004 → May 2009 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT05804149 Background | Aug 2020 → Sep 2022 | menstrual disorder | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT03289403 Comparator | Mar 2018 → Sep 2023 | autoimmune thyroid disease, infertility disorder | Aljazeera Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03390530 Comparator | Jan 2022 → Dec 2025 | intracerebral hemorrhage | Albert Einstein College of Medicine | Withdrawn | No outcome recorded |
| Phase 3 | NCT01436994 Comparator | Jul 2004 → Dec 2014 | thyroid gland disorder | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| — | NCT02509858 Comparator | Feb 2009 → Feb 2014 | diabetes mellitus | Attikon Hospital | Completed | No outcome recorded |
| — | NCT00565890 Comparator | Dec 2005 → Mar 2011 | thyroid gland disorder | Tokyo Women's Medical University | Completed | No outcome recorded |
| — | NCT00715572 Comparator | Mar 2002 → Feb 2004 | hypothyroidism | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | thyroxine | “Thyroxine (T4) administration is advocated in the management of organ donors; however, the bioavailability of oral thyroxine is unknown in this patient population.” PMID 23884915 ↗ Jul 201312“Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range.” NCT01436994 ↗ “Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.” NCT02086799 ↗ |
| Action | Restore | “Thyroxine is then added in a low replacement dose” NCT01436994 ↗ |
| Route | Intravenous | “Patients were randomized to receive either an oral or intravenous dose of T4 (2 μg·kg⁻¹).” PMID 23884915 ↗ Jul 2013 |
| Route | Oral | “Patients were randomized to receive either an oral or intravenous dose of T4 (2 μg·kg⁻¹).” PMID 23884915 ↗ Jul 2013 |